share_log

EF Hutton Assumes Coeptis Therapeutics at Buy, Maintains Price Target of $10

Benzinga ·  May 25, 2023 09:04

EF Hutton analyst Michael King assumes Coeptis Therapeutics (NASDAQ:COEP) with a Buy rating and maintains Price Target of $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment